ABI H0731

Drug Profile

ABI H0731

Alternative Names: ABI-H0731

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Indiana University
  • Developer Assembly Biosciences
  • Class Antivirals; Small molecules
  • Mechanism of Action Viral core protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hepatitis B

Most Recent Events

  • 20 Oct 2017 Adverse events and pharmacokinetics data from a phase Ia/Ib trial in Hepatitis B presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 15 Jun 2017 Phase-I/II clinical trials in Hepatitis B in Hong Kong, Australia (PO) (NCT03109730)
  • 17 Apr 2017 Assembly Biosciences plans a phase I/II trial for Hepatitis B (Monotherapy, Combination therapy) in Australia, Hong Kong, South Korea, Taiwan and United Kingdom (NCT03109730)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top